Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
MYGN 01.08.2025
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

About Gravity Analytica
Recent News
- 01.21.2025 - Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
- 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.15.2025 - Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
Recent Filings
SALT LAKE CITY, Jan. 08, 2025 -Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rdAnnual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).
The presentation will be available through a live webcast in the investor relations section of Myriad’s website atinvestor.myriad.com. An archived edition of the presentation will be available later that day.
About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visitwww.myriad.com.
Investor ContactMatt Scalo(801) 584-3532IR@myriad.com
Media ContactGlenn Farrell(385) 318-3718PR@myriad.com